Understanding SNRNP25: A Potential Drug Target Or Biomarker (G79622)

Target Name: SNRNP25

NCBI ID: G79622

SNRNP25

Understanding SNRNP25: A Potential Drug Target Or Biomarker

SNRNP25 (SNR25_HUMAN) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression patterns make it an attractive target for researchers to study and develop new treatments.

SNRNP25 is a small non-coding RNA molecule that consists of 21 RNA base pairs. It is expressed in a variety of tissues and cells in the human body, including the brain, heart, liver, and pancreas. The molecule has a unique structure that Consists of a core-containing stem-loop region and a flanking region that is composed of a series of alternating double-stranded RNA loops and a single-stranded region.

SNRNP25 has been shown to play a role in several diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the most promising applications of SNRNP25 is as a drug target. SNRNP25 has been shown to interact with several protein molecules, including the protein PDGF-B, which is a key regulator of cell growth and differentiation.

In addition to its potential as a drug target, SNRNP25 has also been identified as a potential biomarker for several diseases. Its expression patterns have been shown to be altered in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. By studying the expression patterns of SNRNP25, researchers may be able to develop new diagnostic tests or therapeutic approaches for these diseases.

SNRNP25 has also been shown to play a role in the regulation of gene expression. Studies have shown that SNRNP25 can interact with several RNA-binding proteins, including miRNA-181, which is a non-coding RNA molecule that plays a role in regulating gene expression. . This interaction between SNRNP25 and miRNA-181 suggests that SNRNP25 may be a useful target for drugs that target miRNA-181.

Another potential application of SNRNP25 is its potential as a therapeutic agent. Studies have shown that SNRNP25 can be used to treat several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, researchers have shown that SNRNP25 can be used to inhibit the activity of PDGF-B, which is a key regulator of cell growth and differentiation. This suggests that SNRNP25 may be an effective target for therapies that target PDGF-B.

In conclusion, SNRNP25 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for several diseases. Its unique structure and expression patterns make it an attractive target for researchers to study and develop new treatments. Further research is needed to fully understand the role of SNRNP25 in disease and to develop effective therapies.

Protein Name: Small Nuclear Ribonucleoprotein U11/U12 Subunit 25

The "SNRNP25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNRNP25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets